SMARCC1 and Hyperglycemia: Since anti-IL17A monoclonal antibodies inhibit serum glucose levels in both mice and humans, ultimately improving hyperglycemia [20], we examined whether SRG3 overexpression modulates IL17-producing immune cells in the adipose tissues of B10.PL mice.